

## Fact Sheet: Sodium iodide [<sup>124</sup>I] injection

### Sodium iodide [<sup>124</sup>I] injection

**-Half-Life: 100.3 hours**

This radiopharmaceutical is for diagnostic use only.

Sodium iodide [<sup>124</sup>I] injection may be given as a small tracer dose to study radioiodine pharmacokinetics. An estimation of the thyroid uptake and the effective elimination half-life in the thyroid prior to radioiodine therapy is used for the calculation of the required therapeutic activity of iodine-131.

Whole Body Scintigraphy in the management of thyroid carcinoma.

### Product Specification

#### Name

Sodium iodide [<sup>124</sup>I] injection

#### Pharmaceutical form

Solution for injection

#### Activity concentration

37 MBq/mL at time and date of calibration

#### Radiochemical purity

> 95.0%

#### Radionuclidic purity

≥ 99.5%

#### pH and composition

7.0 – 10.0 // Sodium chloride, sodium hydrogen phosphate, disodium hydrogen phosphate, sodium thiosulphate, sodium hydroxide, water for injection

#### Storage

Store in the original packaging at controlled room temperature (< 25°C).

#### Expiry

96 hours from the time of calibration

#### Isotope

Iodine-124

### Packaging


15 mL colourless type I glass single-dose vial

### Calibration

Thursday 12:00 p.m. CET, same week

### Availability

Dispensed every Monday // Only available for clinical trials or on patient name basis



### Physical Data


Rad. Type	Energy (keV)	Radiation Intensity (%)
E-AU-L	3.19	63
E-AU-K	22.7	8.3
B+	685.9	11
B+	973.6	12
G-AN	511	45.96
G	602.72	62.9
G	722.78	10.35
G	1509.49	3.13
G	1691.02	10.88

### Decay Table

Physical half-life: 100.3 hours

Hours	0	1	2	3	4	5	6	7	8	9
0	1.000	0.993	0.986	0.979	0.973	0.966	0.959	0.953	0.946	0.940
10	0.933	0.927	0.920	0.914	0.908	0.902	0.895	0.889	0.883	0.877
20	0.871	0.865	0.859	0.853	0.847	0.841	0.836	0.830	0.824	0.818
30	0.813	0.807	0.802	0.796	0.791	0.785	0.780	0.774	0.769	0.764
40	0.758	0.753	0.748	0.743	0.738	0.733	0.728	0.723	0.718	0.713
50	0.708	0.703	0.698	0.693	0.689	0.684	0.679	0.674	0.670	0.665
60	0.661	0.656	0.652	0.647	0.643	0.638	0.634	0.629	0.625	0.621
70	0.616	0.612	0.608	0.604	0.600	0.596	0.591	0.587	0.583	0.579
80	0.575	0.571	0.567	0.563	0.560	0.556	0.552	0.548	0.544	0.541
90	0.537	0.533	0.530	0.526	0.522	0.519	0.515	0.512	0.508	0.505
100	0.501	0.498	0.494	0.491	0.487	0.484	0.481	0.477	0.474	0.471
110	0.468	0.464	0.461	0.458	0.455	0.452	0.449	0.446	0.442	0.439
120	0.436	0.433	0.430	0.427	0.424	0.422	0.419	0.416	0.413	0.410
130	0.407	0.404	0.402	0.399	0.396	0.393	0.391	0.388	0.385	0.383
140	0.380	0.377	0.375	0.372	0.370	0.367	0.365	0.362	0.360	0.357
150	0.355	0.352	0.350	0.347	0.345	0.343	0.340	0.338	0.336	0.333
160	0.331	0.329	0.326	0.324	0.322	0.320	0.318	0.315	0.313	0.311
170	0.309	0.307	0.305	0.303	0.300	0.298	0.296	0.294	0.292	0.290
180	0.288	0.286	0.284	0.282	0.280	0.278	0.277	0.275	0.273	0.271
190	0.269	0.267	0.265	0.263	0.262	0.260	0.258	0.256	0.255	0.253

To obtain a precalibration number, divide by the decay factor.  
For a postcalibration number, multiply by the decay factor.



### More Information

Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal:  $^{124}\text{I}$  PET/CT dosimetric comparisons. *Eur J Nucl Med Mol Imaging*. 2010 Dec;37(12):2267-76. PMID: 20661558.

Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of  $^{124}\text{I}$ -PET/CT in patients with differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2011 May;38 Suppl 1:S48-56. PMID: 21484380.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized  $^{124}\text{I}$  PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. *J Nucl Med*. 2008 Jun;49(6):1017-23. PMID: 18483099.

Kemerink GJ, Visser MG, Franssen R, Beijer E, Zamburlini M, Halders SG, Brans B, Mottaghy FM, Teule GJ. Effect of the positron range of  $^{18}\text{F}$ ,  $^{68}\text{Ga}$  and  $^{124}\text{I}$  on PET/CT in lung-equivalent materials. *Eur J Nucl Med Mol Imaging*. 2011 May;38(5):940-8. PMID: 21287170.

Lopci E, Chiti A, Castellani MR, Pepe G, Antunovic L, Fanti S, Bombardieri E. Matched pairs dosimetry:  $^{124}\text{I}/^{131}\text{I}$  metaiodobenzylguanidine and  $^{124}\text{I}/^{131}\text{I}$  and  $^{86}\text{Y}/^{90}\text{Y}$  antibodies. *Eur J Nucl Med Mol Imaging*. 2011 May;38 Suppl 1:S28-40. PMID: 21484381.

Lubberink M, Herzog H. Quantitative imaging of  $^{124}\text{I}$  and  $^{86}\text{Y}$  with PET. *Eur J Nucl Med Mol Imaging*. 2011 May;38 Suppl 1:S10-8. PMID:21484385.

Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-RD) with  $^{124}\text{I}$  PET for  $^{131}\text{I}$  therapy of thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2011 May;38 Suppl 1:S41-7. PMID: 21484384.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2008 Oct;35(10):1941-59. PMID: 18670773.

**BV CYCLOTRON VU**  
De Boelelaan 1081  
1081 HV Amsterdam  
Postbus 71802  
1008 EA Amsterdam  
The Netherlands

T +31 (0)20 444 9123  
F +31 (0)20 444 9128  
info@cyclotron.nl  
twitter.com/cyclotronvu